Liquid Biopsy, North America, and Lung Cancer Occupying a Major Share in the Market

Minimally Invasive Biopsy Technologies Market

Owing to the market availability of large number of liquid biopsy technologies, the liquid biopsy segment currently accounts for a dominating share in the global minimally invasive biopsy technologies market. However, the market growth in the segment can be attributed to the increasing demand for liquid biopsy and the strong product pipeline. For instance, CNI Second Opinion by Chronix Biomedical is presently under development and is expected to get launched during the forecast period 2019-2030.

Owing to a widespread market presence of leading players and the huge prevalence of cancer, North America presently holds a major share in the global minimally invasive biopsy technologies market. According to the World Cancer Research Fund (WCRF), with an estimated 2 million cases in 2018, lung cancer is the most commonly occurring cancer in men and third-most commonly occurring cancer in women. Due to the widespread presence of cancer, the manufacturers including Biocept, Inc., Chronix Biomedical, Datar Cancer Genetics Limited, Owlstone Medical, Veracyte, Inc., LungLife AI, Inc., and Exosome Diagnostics, among others. are providing diversified range of product offerings for its effective management. Hence, the segment holds a dominating share in global minimally invasive biopsy technologies market.

Request For Free Sample: https://bisresearch.com/industry-report/minimally-invasive-biopsy-technologies-market.html

Europe is expected to witness maximum growth at a CAGR of 15.40%, during the forecast period 2019-2030. The growth in the region can be attributed to the rising number of funding and investments for research on minimally invasive biopsy technologies and also to the increasing cancer burden. For instance, the European Union’s research and innovation programme, Horizon 2020, awarded $6.94 million to a joint consortium on liquid biopsy and Magnetic Resonance Imaging. The initiative aims at analyzing the effects of liquid biopsy and MRI in the diagnosis of breast and colon cancer.

Comments

Chatbots Increasing Efficiency in Healthcare Market

Chatbots are one of the prominent technologies currently being integrated into the healthcare system. The chatbots are not considered as the SaMD (software as medical device) as they do not participate in clinical decision-making process, rather, they act as the personal healthcare assistant as well as the trainer for its users. Click Here To Get Detailed Description of Chatbots in Healthcare Market The usage of chatbots in the healthcare has gained popularity since 2013, when Babylon Health, the first healthcare chatbot company of the U.K. was launched. The company offered symptom checker chatbot and has started using the same chatbot as a health checker as well. The industry comprises the bot developers, platform providers, content providers, and the interface providers. Since there are no regulatory bodies such as FDA and MHRA directly governing the usage of chatbots, launching the chatbot is convenient for the developers. New start-ups are coming up wit...

Wireless Charging Technology – Analyzing the Market Drivers and Restraints

Wireless charging technology eliminates the use of wires to power devices and enables a device to be charged automatically when placed near a transmitter. The wireless charging technology is however, not new in the world of technology, rather, has been in existence since the late 1800s. With the incorporation of the technology in smartphones, it has been experiencing a massive boost in popularity. Request the Sample @ https://bisresearch.com/requestsample?id=645&type=download According to the latest market intelligence report by BIS Research titled “ Global Wireless Charging Market - Analysis and Forecast (2018-2023) ,” the market was valued at $2.58 billion in 2017 and is projected to grow at a CAGR of 40.97%, during the forecast period and reach $20.97 billion by 2023. The market is estimated to witness the highest growth in the Asia-Pacific (APAC) region during the forecast period (2018-2023). The wireless charging technology is not only limited to the sm...

Neoantigens Vaccines Can Bridge the Treatment Gap by Training the Immune System to Recognize Tumor Cells

As per BIS Research analysis, the neoantigen cancer vaccine market is projected to reach $1826.1 million by 2030 from $227.1 million in 2023, at a CAGR of 34.69%. Growth in this market is expected to be driven by the ever-rising patient pool of different cancers and significant investment in research for development for cancer neoantigen vaccines to fill in the current treatment gaps. However, there are significant challenges that are restraining the market growth. These challenges include the high cost of therapy (personalized cancer vaccines), manufacturing complications, and lack of therapeutic biomarkers and assays. The market is still at the nascent phase with more than two-thirds of the neovaccines in the early stages of development. However, few neovaccines companies such as OSE Immunotherapeutics, Immunovative Therapeutics, Medigene, and Roche have positioned themselves to launch their neovaccines in the market within the upcoming years. That being said, the neovacc...

BIS Research ( Business Intelligence and Strategy Research)

Search This Blog